Phase I, Phase I

A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients With Solid Tumors With KRASG12D Mutation

Volunteers
Health Professionals

What is the purpose of this trial?

Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Ingrid Palma

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Patricia LoRusso, DO
Amy and Joseph Perella Professor of Medicine (Medical Oncology); Chief, Experimental Therapeutics; Associate Cancer Center Director, Experimental Therapeutics

Sub-Investigators

Last Updated
11/26/2024
Study HIC
#2000037159